<DOC>
	<DOCNO>NCT00651443</DOCNO>
	<brief_summary>The purpose study evaluate mechanism ( ) action galiximab subject previously untreated follicular NHL .</brief_summary>
	<brief_title>Mechanism Action Galiximab Subjects With Previously Untreated Follicular Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Written inform consent ( sign date ) . Age equal great 18 time consent . Histologically confirm follicular NHL accord Revised European American Lymphoma ( REAL ) / World Health Organization ( WHO ) classification ( initial diagnosis ) Grades 1,2 , 3a . At least 2 malignant lymph node similar size ( &gt; 1 cm minimal dimension ) location readily accessible excisional biopsy time study entry . Consent 1 pretreatment 1 posttreatment excisional biopsy accessible tumor . Acceptable hematologic , hepatic , renal function parameter . WHO Performance Status equal less 2 . Subjects reproductive potential must agree follow accepted birth control method . Presence lymphoma CNS . Previous systemic anticancer treatment NHL ( include limit radiation , myeloablative , investigational therapy ) . Concurrent treatment systemic steroid within 14 day Day 1 . Evidence transform lymphoma . Presence malignancy within 3 year Study Day 1 ( except adequately treat carcinoma situ cervix , ductal carcinoma situ ( DCIS ) breast , basal squamous cell skin cancer ) . History HIV infection AIDS . Serious nonmalignant disease . Pregnant . Inability comply study followup procedure . Any disease , metabolic dysfunction , physical examination finding , clinical laboratory find contraindicates use investigational drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>galiximab</keyword>
	<keyword>Untreated NHL</keyword>
	<keyword>antibody</keyword>
	<keyword>open-label</keyword>
</DOC>